Should Investors Bet on Gilead Sciences Version 3.0?

Should Investors Bet on Gilead Sciences Version 3.0?


CEOMark Pruzanski presented late Wednesday at the J.P. Morgan Healthcare Conference. Pruzanski obviously focused on Intercept's achievements and plans.



from Biotech News